Sen Xu
Wuhan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: March 25, 2026
Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors.
Journal: Cell
Published: January 18, 2023
Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB-Triggered SASP in Cancer-Associated Fibroblasts.
Journal: Molecular cancer therapeutics
Published: June 28, 2022
TAGLN mediated stiffness-regulated ovarian cancer progression via RhoA/ROCK pathway.
Journal: Journal of experimental & clinical cancer research : CR
Published: May 28, 2021
Deep learning-enabled pelvic ultrasound images for accurate diagnosis of ovarian cancer in China: a retrospective, multicentre, diagnostic study.
Journal: The Lancet. Digital health
Published: January 19, 2021
PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer.
Journal: NPJ precision oncology
Published: August 24, 2020
Corrigendum to "Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer" [Cancer Lett 415 (20-29)].
Journal: Cancer letters
Published: November 20, 2019
Correction: Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer.
Journal: The Journal of experimental medicine
Published: October 09, 2019
Correction: Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis.
Correction: Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis.
Journal: Anti-cancer agents in medicinal chemistry
Published: June 18, 2019
Last Updated: 09/26/2026